Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of a 20-valent pneumococcal conjugate vaccine in healthy children aged 2 months to 5 years
CTR20251041Phase 2Active
- Sponsor
- Beijing Minhai Biological
- Start
- Mar 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of 20-valent Pneumococcal Polysaccharide Conjugate Vaccine in pneumococcal disease, sponsored by Beijing Minhai Biological. Started Mar 2025; status: active.
02
Drugs
20-valent Pneumococcal Polysaccharide Conjugate Vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on CTR20251041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251041.